Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Quest Diagnostics ( (DGX) ) is now available.
On April 27, 2026, Quest Diagnostics priced a $500 million public offering of 5.000% senior notes due 2036 under its shelf registration statement. The company entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC, and expects to receive the net proceeds at closing on May 6, 2026, subject to customary conditions.
Quest plans to use the proceeds for general corporate purposes, including potential repayment of existing debt such as its $500 million 3.45% senior notes maturing June 1, 2026. The refinancing move is set to extend the company’s debt maturity profile and may lower near-term refinancing risk, supporting liquidity and financial flexibility for its core diagnostic services business.
The most recent analyst rating on (DGX) stock is a Hold with a $220.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Neutral.
DGX scores strongest on forward outlook, driven by raised 2026 guidance and strong Q1 growth, supported by generally solid and stable financial performance. The overall score is held back by mixed near-term technical momentum and watch-items around cash conversion, leverage, and mix/regulatory headwinds highlighted on the call.
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
Quest Diagnostics is a leading U.S. provider of diagnostic information services, connecting clinicians and consumers with laboratory insights to support disease detection, treatment decisions, and healthcare management. The company serves about half of U.S. physicians and hospitals and one in three American adults annually, supported by a workforce of nearly 57,000 employees.
With a focus on delivering smarter, simpler testing, Quest leverages its extensive national reach and lab network to help identify and treat disease, empower healthier behaviors, and improve care management. Its scale and penetration in the healthcare system position the company as a critical infrastructure player in clinical diagnostics and population health.
Average Trading Volume: 1,016,133
Technical Sentiment Signal: Buy
Current Market Cap: $21.5B
For an in-depth examination of DGX stock, go to TipRanks’ Overview page.